A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Except as otherwise indicated herein or as the context otherwise requires, references in this annual report on Form 10-K to "MacroGenics," the "company," "we," "us" and "our" refer to MacroGenics, Inc. and its consolidated subsidiaries. “MacroGenics®, the MacroGenics logo, DART®, TRIDENT® and the phrases Breakthrough Biologics, Life-Changing Medicines® and Developing Breakthrough Biologics, Life-Changing Medicines® are our trademarks. The other trademarks, trade names and service marks appearing in this report are the property of their respective owners. We are a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer. We generate our pipeline of product candidates from our proprietary suite of antibody technology platforms.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 128M | 150M | 59M | 152M | - | 105M |
| Net Income | -76M | -67M | -9.1M | -120M | -202M | -130M |
| EPS | $-1.21 | $-1.07 | $-0.15 | $-1.95 | $-3.37 | $-2.47 |
| Free Cash Flow | -165M | -72M | -80M | -91M | -150M | -118M |
| ROIC | -33.1% | -57.7% | -5.9% | -84.3% | -84.3% | -43.8% |
| Gross Margin | 99.8% | 99.4% | 98.9% | 97.8% | - | 100.0% |
| Debt/Equity | 0.00 | 1.25 | 0.96 | 0.97 | 0.40 | 0.28 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -114M | -111M | -168M | -121M | -203M | -131M |
| Operating Margin | -89.0% | -73.7% | -286.4% | -79.9% | - | -125.0% |
| ROE | -113.3% | -49.9% | -5.9% | -84.3% | -84.3% | -43.8% |
| Shares Outstanding | 63M | 63M | 60M | 61M | 60M | 53M |
MACROGENICS INC passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 99.0%.
MACROGENICS INC (MGNX) has a 5-year average return on invested capital (ROIC) of -55.2%. This is below average and may indicate limited pricing power.
MACROGENICS INC (MGNX) has a market capitalization of $221M. It is classified as a small-cap stock.
MACROGENICS INC (MGNX) does not currently pay a regular dividend.
MACROGENICS INC (MGNX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
MACROGENICS INC (MGNX) reported annual revenue of $150 million in its most recent fiscal year, based on SEC EDGAR filings.
MACROGENICS INC (MGNX) has a net profit margin of -44.7%. The company is currently unprofitable.
MACROGENICS INC (MGNX) generated $-72 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
MACROGENICS INC (MGNX) has a debt-to-equity ratio of 1.25. This indicates moderate leverage.
MACROGENICS INC (MGNX) reported earnings per share (EPS) of $-1.07 in its most recent fiscal year.
MACROGENICS INC (MGNX) has a return on equity (ROE) of -49.9%. A negative ROE may indicate losses or negative equity.
MACROGENICS INC (MGNX) has a 5-year average gross margin of 99.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 14 years of financial data for MACROGENICS INC (MGNX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
MACROGENICS INC (MGNX) has a book value per share of $1.85, based on its most recent annual SEC filing.